Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19618269 | 0.89 | KDM4E (0.52) | KDM4EHTTGAATHRBMAPT | |
| SCHEMBL19618263 | 0.84 | KDM4E (0.46) | KDM4EHTTGAATHRBMAPT | |
| SCHEMBL19618204 | 0.79 | HPGD (0.42) | KDM4EHTTGAAMAPTALDH1A1 | |
| SCHEMBL23838686 | 0.72 | MAPT (0.47) | MAPTALDH1A1HPGDSMN1; SMN2TSHR | |
| SCHEMBL19618268 | 0.72 | PRMT6 (0.55) | HTTGAAMAPTALDH1A1HPGD | |
| SCHEMBL17570358 | 0.71 | NOTUM (0.50) | KDM4EGAAMAPTALDH1A1LMNA | |
| SCHEMBL20756486 | 0.71 | HTT (0.55) | KDM4EHTTGAAMAPTALDH1A1 | |
| SCHEMBL16812991 | 0.71 | ALDH1A1 (0.49) | MAPTALDH1A1HPGDSMN1; SMN2TSHR | |
| SCHEMBL10264449 | 0.70 | MAPT (0.41) | KDM4EHTTTHRBMAPTALDH1A1 | |
| SCHEMBL17570348 | 0.69 | NOTUM (0.47) | KDM4EGAAMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118735-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | GRA VENTURE FUND, LLC | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118735-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | KDM4E 1707/4885HTT 2551/4885GAA 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.